Navigation Links
Yongye International Announces First Quarter 2010 Results
Date:5/12/2010

sales, in the same period last year. The increase in margin was primarily due to additional expenses related to advertising and promotional activities and, to a lesser extent, increases in freight expenses, salaries, professional fees and travel expenses. Operating income was $5.6 million compared to $3.3 million in the same period last year.

Net income was $4.4 million, or $0.10 per diluted share, in the first quarter of 2010, compared to net income of $3.3 million, or $0.12 per diluted share, in the first quarter of 2009. The Company recorded a non-cash change in fair value of derivative liabilities of $12,534 in the first quarter of 2010. Excluding the impact of this non-cash item, adjusted net income was $4.4 million, or $0.10 per diluted share, compared to adjusted net income of $3.1 million, or $0.12 per diluted share in the same period last year.(*)

    (*) See the table following this press release for a reconciliation of net
        income and diluted EPS to exclude the non-cash change in fair value of
        derivative liabilities.

Financial Condition

As of March 31, 2010, the Company had $51.0 million in cash, compared to $65.5 million as of December 31, 2009. Working capital was $98.9 million, compared to $107.7 million at the end of 2009. As of year-end 2009, the Company had only $0.5 million in long
'/>"/>

SOURCE Yongye International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. Yongye International Announces Conference Call to Discuss First Quarter Fiscal Year 2010 Results
2. Yongye International to Present at Upcoming Investor Conferences
3. Yongye International, Inc. Begins Construction of New Production Facility
4. Yongye International Announces Conference Call to Discuss Fourth Quarter and Fiscal Year 2009 Results
5. Yongye International Announces Conference Call to Discuss Third Quarter 2009 Results
6. Yongye International Announces 2010-2012 Strategic Plan
7. Yongye International Announces Expansion of Research and Development Center
8. Yongye International Announces Branded Store Network Increases Over 40% to 5,000 Stores
9. Yongye Biotechnology International Receives License to Manufacture Products
10. Yongye Biotechnology International Raises $ 9.0 Million In Private Placement, Raises Guidance
11. Yongye Biotechnology Distributor has Record Breaking Single Store Sales Day
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/30/2015)... CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC) ... today announced data from PERSIST-1 – a randomized Phase ... myelofibrosis – in a late-breaking oral session at the ... Clinical Oncology (ASCO), May 29-June 2, 2015 in ... oral multikinase inhibitor with specificity for JAK2 and FLT3. ...
(Date:5/30/2015)... CHICAGO and RARITAN, N.J. ... the international, multi-center, open-label, two-part, single-arm Phase 2 ... – an investigational, human anti-CD38 monoclonal antibody – ... percent (95% CI, 20.8-38.9), as assessed by an ... multiple myeloma. The ORR was consistent among the ...
(Date:5/30/2015)... 2015  Caris Life Sciences® today announced the ... researchers identified biomarker changes, including key driver mutations, ... changes in response to therapy as the disease ... subset of a larger study analyzing 1,245 glioma ... These data utilizing Caris Molecular Intelligence®, the company,s ...
(Date:5/29/2015)... HILL, N.C. , May 29, 2015 /PRNewswire/ ... medical affairs function into roles involving clinical development, ... As its responsibilities have grown, Medical Affairs has ... function as a global group. And while its ... find it challenging to identify strong performance metrics ...
Breaking Biology Technology:Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 2Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 3Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 4Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 5Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 6Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 7Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 8Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 9Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 10Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 2Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 3Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 4Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 5Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 6Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 7Caris Life Sciences Paired Tumor Data Identifies Key Driver Mutations and Confirms Tumor Heterogeneity in High-Grade Glioma Samples 2Caris Life Sciences Paired Tumor Data Identifies Key Driver Mutations and Confirms Tumor Heterogeneity in High-Grade Glioma Samples 3Caris Life Sciences Paired Tumor Data Identifies Key Driver Mutations and Confirms Tumor Heterogeneity in High-Grade Glioma Samples 4Creating an Effective Pharmaceutical Medical Affairs Group with Global Capabilities 2
... New Jersey, December 5, Rosetta Genomics, Ltd. (NASDAQ: ... as biomarkers,reported today its consolidated financial results for the ... The company recorded revenues ... were recorded from the date of acquisition of Parkway ...
... Sky One Medical,Inc. ("China Sky One Medical" or "the ... pharmaceutical company producing over-the-counter drugs in,the People,s Republic of ... and President of China Sky One Medical took part ... Perspective. , As ...
... today announced that David Hung, M.D., president and chief,executive officer, will be ... Conference on Thursday, December 11, in New York: , ... Eastern Time, -- "The Challenge of Alzheimer,s Disease" from ... A live audio webcast of each panel ...
Cached Biology Technology:Rosetta Genomics Reports Third Quarter 2008 Financial Results; Records First Revenues of $705,000; $7.4 Million Added to Available Cash Due to Repurchase of ARS 2Rosetta Genomics Reports Third Quarter 2008 Financial Results; Records First Revenues of $705,000; $7.4 Million Added to Available Cash Due to Repurchase of ARS 3Rosetta Genomics Reports Third Quarter 2008 Financial Results; Records First Revenues of $705,000; $7.4 Million Added to Available Cash Due to Repurchase of ARS 4Rosetta Genomics Reports Third Quarter 2008 Financial Results; Records First Revenues of $705,000; $7.4 Million Added to Available Cash Due to Repurchase of ARS 5Rosetta Genomics Reports Third Quarter 2008 Financial Results; Records First Revenues of $705,000; $7.4 Million Added to Available Cash Due to Repurchase of ARS 6Rosetta Genomics Reports Third Quarter 2008 Financial Results; Records First Revenues of $705,000; $7.4 Million Added to Available Cash Due to Repurchase of ARS 7Rosetta Genomics Reports Third Quarter 2008 Financial Results; Records First Revenues of $705,000; $7.4 Million Added to Available Cash Due to Repurchase of ARS 8Rosetta Genomics Reports Third Quarter 2008 Financial Results; Records First Revenues of $705,000; $7.4 Million Added to Available Cash Due to Repurchase of ARS 9Rosetta Genomics Reports Third Quarter 2008 Financial Results; Records First Revenues of $705,000; $7.4 Million Added to Available Cash Due to Repurchase of ARS 10China Sky One Medical, Inc. Interviewed in The China Perspective 2China Sky One Medical, Inc. Interviewed in The China Perspective 3Medivation Announces Participation in RBC Capital Markets 2008 Healthcare Conference 2
(Date:5/14/2015)... and Markets ( http://www.researchandmarkets.com/research/5whpxg/fingerprint ) has announced ... Smart Mobile Devices " report to their offering. ... watershed year for fingerprint sensors in smartphones and tablets, ... fingerprint sensors a raison d,etre in the mobile milieu ... must-have feature in flagship smartphones. The key ...
(Date:5/11/2015)... , May 11, 2015  Through a well-rounded UAS ... had a strong showing at AUVSI,s Unmanned 2015 ... representatives of Ohio,s UAS industry met ... abroad from all points along the UAS ecosystem. ... Coalition,s (DDC) Vice President for Aerospace Rich Knoll . ...
(Date:5/8/2015)... May 8, 2015 Synaptics Inc. (NASDAQ: SYNA ... that members of the executive management team will present at ... Technology, Media and Telecom Conference Date: May 18, 2015 ... Boston, MA Cowen and Company ... 2:45pm ET Location: The New York Palace Hotel, ...
Breaking Biology News(10 mins):Global Smart Mobile Devices Fingerprint Sensors Market 2015-2019: Key Vendors are Authentec, Validity Sensors, Fingerprint Cards, Next Biometrics Group. IDEX, and Qualcomm 2Ohio Flies High at Unmanned '15, Sets Stage for Ohio UAS Conference 2Synaptics to Present at Upcoming Investor Conferences 2
... Wiley Interdisciplinary Reviews (WIREs), the pioneering new publications launched ... the most prestigious awards in scholarly publishing at the ... Professional & Scholarly Excellence (PROSE Awards) named the WIREs ... the association,s top prize, established in 1976 to recognise ...
... of Medicine believe they may have discovered how the ... The findings will be presented at the Annual Scientific ... Chicago by Errol Norwitz, M.D., professor in the Department ... Preterm birthdelivery prior to 37 weeks gestationhas become ...
... Eastern Illinois Foodbank shared results of a national study ... organization. The study is completed every four years by ... emergency food distribution throughout the United States. Craig Gundersen, ... Consumer Economics at the University of Illinois, is a ...
Cached Biology News:WIREs win 3 prizes at the PROSE awards 2U of I faculty assist in evaluating US food security programs 2
... A perfect complement to high-speed analytical techniques, the AutoTrace SPE is a powerful, ... the cartridge conditioning, sample loading and elution steps for large volumes aqueous solution ... ... ...
... optically clear polystyrene with frosted labeling ... for cell counting. 100% integrity tested. ... new product number, created to easily ... no availability yet, please order under ...
Cell Culture Flask, nontreated polystyrene...
... The Corning CellBIND surface is produced ... a more hydrophilic surface giving more consistent, ... yields. CellBIND enhances cell attachment and growth ... serum-free medium. • CellBIND may provide a ...
Biology Products: